|1.||Paglietti, Giuseppe: 3 articles (04/2009 - 03/2006)|
|2.||Loriga, Mario: 3 articles (04/2009 - 03/2006)|
|3.||Carta, Antonio: 2 articles (04/2009 - 03/2006)|
|4.||Corona, Paola: 2 articles (04/2009 - 01/2008)|
|5.||Haymerle, Georg: 1 article (11/2015)|
|6.||Heiduschka, Gregor: 1 article (11/2015)|
|7.||Brunner, Markus: 1 article (11/2015)|
|8.||Thurnher, Dietmar: 1 article (11/2015)|
|9.||Kotowski, Ulana: 1 article (11/2015)|
|10.||Kadletz, Lorenz: 1 article (11/2015)|
09/01/2008 - "These data indicate that 1,4-di-N-oxide quinoxalines hold promise for the treatment of tuberculosis."
01/01/2005 - "Our discussion and observations are concentrated on chemotherapeutic potential of alphabetically listed twenty-seven new structural classes of anti-tuberculosis agents that include:- acetamides, 5-arylidene-2-thiohydantoins, benzoxazoles and benzothiazoles, benzoic acid hydrazones, benzoxazines, carbohydrates, chalcones, coumarins, deazapteridines, imidazoles, indoloquinazolinones, isothiosemicarbazones, mycobactins, 1,8-naphthyridines, phenazines, purines, pyridines, N-pyridinylsalicylamides, pyrimidines and thymidines, pyrroles, quinolines, quinoxalines, terpenes, thiadiazine thiones, thiolactomycines, toludines, and triazoles."
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/01/2015 - "The anticancer potential of quinoxalines has been described in various tumor entities. "
04/01/2009 - "A series of novel 5,7-diamino-3-phenyl-2-benzylamino, 2-phenoxy, and 2-thiophenyl substituted quinoxalines has been designed, synthesized and evaluated for their in vitro antitumor activity towards cell lines of nine different types of human cancers. "
01/01/2008 - "Several diamino quinoxalines were designed, synthesized and evaluated as anti-tumor agents. "
03/01/2006 - "In vitro data show that many quinoxalin-2-ones and quinoxalines potentiate the antiproliferative activity of Doxo and VCR in tumor-derived MDR cell lines. "
01/01/2011 - "The anti-tumor activity of synthesized quinoxalines 1-21 has been evaluated by studying their possible inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). "
|4.||Ganglion Cysts (Ganglion)
06/12/1999 - "Quinoxalines had differential effects on the firing rates of ON- and OFF-center ganglion cells: ON-cells were reduced, while OFF-cells were increased. "
06/12/1999 - "ON-sustained ganglion cells were highly sensitive to the quinoxalines, which reduced their light-evoked firing, while the firing of ON-transient cells remained as NMDA-mediated light-responses. "
|5.||Skin Neoplasms (Skin Cancer)
|4.||Benzoic Acid (Ucephan)